He has served as a member of our board of directors since September 2012, and as chair of our board of directors since September 2014. Since October 2025, Mr. Bradbury has served as Chairman of Equillium, Inc., a publicly traded biotechnology company, that he cofounded and also served as its Executive Chairman from January 2020 until September 2025, CEO from June 2018 until December 2019 and President from March 2017 until June 2018. Mr. Bradbury is the founder of, and has served as the managing member of BioBrit, LLC, a life sciences consulting and investment firm, since September 2012. Mr. Bradbury served as President, CEO and a director of Amylin Pharmaceuticals, Inc. from March 2007 until Amylin s acquisition by Bristol-Myers Squibb Company in August 2012. Prior to Amylin, Mr. Bradbury worked in marketing and sales for ten years at SmithKline Beecham Pharmaceuticals. Mr. Bradbury serves on the board of Equillium, Inc. and Vivani Medical Inc., as well as a number of privately held companies. He previously served on the board of directors of the following publicly traded companies: Intercept Pharmaceuticals, Inc., a biopharmaceutical company, from 2016 to 2023; Biocon Limited, an Indian biopharmaceutical company, from 2013 to 2022; Corcept Therapeutics, Inc., a pharmaceutical company, from 2012 to 2019; Geron Corporation, a biotechnology company, from 2012 to 2019; and Illumina, Inc., a biotechnology company, from 2004 to 2017. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from the University of West London in the United Kingdom. Independent Board Chair Age: 64 Director since: 2012 Committees: None Our Nominating and Corporate Governance Committee and board of directors believe that Mr. Bradbury s extensive experience as a life sciences executive and his other executive and boards of directors experience qualify him to serve on our board of directors.